<DOC>
	<DOCNO>NCT01714908</DOCNO>
	<brief_summary>Erlotinib concurrent radiotherapy superior efficacy comparable safety profile unresectable stage III non-small cell lung cancer ( NSCLC ) patient activate mutation epidermal growth factor receptor ( EGFR ) exon 19 21 versus etoposide plus cis-platin concurrent radiotherapy .</brief_summary>
	<brief_title>Phase II Study Erlotinib With Concurrent Radiotherapy Unresectable NSCLC With Activating Mutation EGFR Exon 19 21</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>NSCLC confirm histopathology cytology ; Stage IIA IIIB NSCLC accord Tumor Node Metastasis ( TMN ) stag Lung Staging Standard version 7 2009 , unresectable ; Has active mutation EGFR exon 19 21 ; Has measurable lesion [ accord Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 , must least one evaluable lesion long dimension &gt; = 10mm ; evaluable lesion lymph node , short dimension measure &gt; =15mm ] ; Eastern Cooperative Oncology Group ( ECOG ) performance status ( PS ) 01 ; expectancy life &gt; = 12 week ; Had treat HERtargeting agent ; Had systemic anitNSCLC treatment ; Had local radiotherapy NSCLC ; Has upper gastrointestinal physiological disorder , malabsorption syndrome , intolerance oral medication , active peptic ulcer ; Diagnosed malignant tumor besides NSCLC within 5 year prior study treatment ( except simple surgical resection 5year disease free survival , cure situ cervical carcinoma , cure basal cell carcinoma bladder epithelial tumor ) ; Any evidence indicate moderate severe chronic obstructive pulmonary disease ( COPD ) ; Known hypersensitivity platinum , etoposide , EGFRTyrosine Kinase Inhibitor ( TKI ) agent relevant component formulation ; Uncontrolled eye inflammation infection , potential circumstance lead eye inflammation infection ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>NSCLC</keyword>
	<keyword>EGFR mutation</keyword>
	<keyword>unresectable</keyword>
	<keyword>erlotinib</keyword>
	<keyword>concurrent radiotherapy</keyword>
</DOC>